JP5099951B2 - 副作用が減少されたヘモグロビン組成物 - Google Patents

副作用が減少されたヘモグロビン組成物 Download PDF

Info

Publication number
JP5099951B2
JP5099951B2 JP2001537359A JP2001537359A JP5099951B2 JP 5099951 B2 JP5099951 B2 JP 5099951B2 JP 2001537359 A JP2001537359 A JP 2001537359A JP 2001537359 A JP2001537359 A JP 2001537359A JP 5099951 B2 JP5099951 B2 JP 5099951B2
Authority
JP
Japan
Prior art keywords
hemoglobin
mammal
globin
blood
mutation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2001537359A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003515533A (ja
JP2003515533A5 (https=
Inventor
ダグラス エル． ルッカー，
アイジードア ゼット． アポストル，
エリック エイ． ブルッカー，
マイケル ピー． ドイル，
デイビッド エル． フォスター，
クリストファー ビー． グラスコック，
ジェイムズ シー． ハートマン，
ジョフリー エフ． リー，
ダグラス ディー． レモン，
エドウィン ジー． ムーア，
ジェーン ピー． リチャーズ，
マイケル アール． シック，
スティーブン ピー． トリンブル，
デイビッド ペレイラ，
トン−タット ハイ，
ケネス イー． バーホップ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baxter Healthcare SA
Baxter International Inc
Original Assignee
Baxter Healthcare SA
Baxter International Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Healthcare SA, Baxter International Inc filed Critical Baxter Healthcare SA
Publication of JP2003515533A publication Critical patent/JP2003515533A/ja
Publication of JP2003515533A5 publication Critical patent/JP2003515533A5/ja
Application granted granted Critical
Publication of JP5099951B2 publication Critical patent/JP5099951B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/795—Porphyrin- or corrin-ring-containing peptides
    • C07K14/805—Haemoglobins; Myoglobins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2001537359A 1999-11-12 2000-11-10 副作用が減少されたヘモグロビン組成物 Expired - Fee Related JP5099951B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16528999P 1999-11-12 1999-11-12
US60/165,289 1999-11-12
PCT/US2000/030857 WO2001034648A1 (en) 1999-11-12 2000-11-10 Reduced side-effect hemoglobin compositions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011030290A Division JP2011098985A (ja) 1999-11-12 2011-02-15 副作用が減少されたヘモグロビン組成物

Publications (3)

Publication Number Publication Date
JP2003515533A JP2003515533A (ja) 2003-05-07
JP2003515533A5 JP2003515533A5 (https=) 2007-12-27
JP5099951B2 true JP5099951B2 (ja) 2012-12-19

Family

ID=22598286

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2001537359A Expired - Fee Related JP5099951B2 (ja) 1999-11-12 2000-11-10 副作用が減少されたヘモグロビン組成物
JP2011030290A Pending JP2011098985A (ja) 1999-11-12 2011-02-15 副作用が減少されたヘモグロビン組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2011030290A Pending JP2011098985A (ja) 1999-11-12 2011-02-15 副作用が減少されたヘモグロビン組成物

Country Status (8)

Country Link
US (2) US6670323B1 (https=)
EP (2) EP2292657A1 (https=)
JP (2) JP5099951B2 (https=)
AU (1) AU784195B2 (https=)
CA (1) CA2391226A1 (https=)
NO (1) NO20022229L (https=)
WO (1) WO2001034648A1 (https=)
ZA (1) ZA200203817B (https=)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2292657A1 (en) * 1999-11-12 2011-03-09 Baxter Biotech Technology S.A.R.L. Reduced side-effect hemoglobin compositions
DE10224750A1 (de) 2002-06-04 2003-12-24 Fresenius Medical Care De Gmbh Vorrichtung zur Behandlung einer medizinischen Flüssigkeit
US7092752B2 (en) * 2002-07-27 2006-08-15 Sheng-Xing Ma Skin acupoint/meridian nitric oxide collection kit and method thereof
US9138707B2 (en) 2002-12-10 2015-09-22 Sy Kimball Portable, nitric oxide generator
DK1449535T3 (da) * 2003-02-18 2006-09-11 Clinique La Prairie Res Sa Præparater der omfatter fötalt hæmoglobin og bakterieendotoksin samt eventuelt fötale leverbestanddele
AU2005279780B2 (en) * 2004-08-31 2011-02-03 Sangart, Inc. Methods to enhance hemodynamic stability using oxygen carrying compositions
US7976866B2 (en) * 2004-12-06 2011-07-12 Opremcak E Mitchel Bandage and method for vital bleaching of skin
US7935074B2 (en) 2005-02-28 2011-05-03 Fresenius Medical Care Holdings, Inc. Cassette system for peritoneal dialysis machine
US8741832B2 (en) * 2005-06-10 2014-06-03 Albert Einstein College Of Medicine Of Yeshiva University Pegylated albumin and uses thereof
WO2007058678A2 (en) * 2005-06-10 2007-05-24 Albert Einstein College Of Medicine Of Yeshiva University Uses of pegylated albumin
US8197231B2 (en) 2005-07-13 2012-06-12 Purity Solutions Llc Diaphragm pump and related methods
US8720436B2 (en) * 2008-01-31 2014-05-13 Genosys, Inc. Nitric oxide gel apparatus and method
US8434475B2 (en) * 2008-01-31 2013-05-07 Genosys, Inc. Nitric oxide reactor and distributor apparatus and method
US9649467B2 (en) 2008-01-31 2017-05-16 Syk Technologies, Llc Nitric oxide reactor and distributor apparatus and method
US20090247619A1 (en) * 2008-03-06 2009-10-01 University Of Kentucky Cannabinoid-Containing Compositions and Methods for Their Use
US8501090B2 (en) * 2008-03-24 2013-08-06 Christian S. Minton Anti-microbial gas apparatus and method
US8192401B2 (en) 2009-03-20 2012-06-05 Fresenius Medical Care Holdings, Inc. Medical fluid pump systems and related components and methods
WO2011008858A1 (en) * 2009-07-15 2011-01-20 Fresenius Medical Care Holdings, Inc. Medical fluid cassettes and related systems and methods
US8720913B2 (en) 2009-08-11 2014-05-13 Fresenius Medical Care Holdings, Inc. Portable peritoneal dialysis carts and related systems
US8685467B2 (en) 2010-08-03 2014-04-01 J. W. Randolph Miller Nitric oxide generation, dilution, and topical application apparatus and method
US8609815B2 (en) * 2010-09-02 2013-12-17 Sangart, Inc. Methods for preparing stable deoxygenated PEG-hemoglobin conjugate solutions comprising an antioxidant
DE102010053973A1 (de) 2010-12-09 2012-06-14 Fresenius Medical Care Deutschland Gmbh Medizinisches Gerät mit einer Heizung
EP2654825B1 (en) 2010-12-20 2017-08-02 Fresenius Medical Care Holdings, Inc. Medical fluid cassettes and related systems and methods
US9624915B2 (en) 2011-03-09 2017-04-18 Fresenius Medical Care Holdings, Inc. Medical fluid delivery sets and related systems and methods
AU2012254069B2 (en) 2011-04-21 2015-10-08 Fresenius Medical Care Holdings, Inc. Medical fluid pumping systems and related devices and methods
EP2550973B1 (en) 2011-07-23 2013-08-28 SastoMed GmbH Wound spray
KR101931403B1 (ko) 2011-09-23 2018-12-21 블루버드 바이오, 인코포레이티드. 개선된 유전자 치료 방법
ES2769270T3 (es) 2011-09-30 2020-06-25 Bluebird Bio Inc Compuestos para transducción viral mejorada
US9186449B2 (en) 2011-11-01 2015-11-17 Fresenius Medical Care Holdings, Inc. Dialysis machine support assemblies and related systems and methods
IN2014MN02089A (https=) * 2012-03-20 2015-09-11 Einstein Coll Med
US20130261412A1 (en) * 2012-03-28 2013-10-03 II Robert Lawrence Reed System and method for managing fluid levels in patients based upon creatinine clearance
US9610392B2 (en) 2012-06-08 2017-04-04 Fresenius Medical Care Holdings, Inc. Medical fluid cassettes and related systems and methods
US9500188B2 (en) 2012-06-11 2016-11-22 Fresenius Medical Care Holdings, Inc. Medical fluid cassettes and related systems and methods
JP2014062050A (ja) * 2012-09-19 2014-04-10 Fujifilm Corp 多価官能マレイミド系重合性化合物、これを含む硬化組成物およびインク組成物
US9561323B2 (en) 2013-03-14 2017-02-07 Fresenius Medical Care Holdings, Inc. Medical fluid cassette leak detection methods and devices
US10517817B2 (en) 2013-05-09 2019-12-31 Syk Technologies, Llc Deep topical systemic nitric oxide therapy apparatus and method
US10117985B2 (en) 2013-08-21 2018-11-06 Fresenius Medical Care Holdings, Inc. Determining a volume of medical fluid pumped into or out of a medical fluid cassette
AR102048A1 (es) 2014-08-12 2017-02-01 Baxalta Inc Producción del factor x completamente procesado y funcional en un sistema de expresión de mamífero de secreción de furina
ES2968200T3 (es) 2016-01-27 2024-05-08 Syk Tech Llc Aparato y métodos de aplicación tópica de óxido nítrico
WO2017139561A1 (en) 2016-02-12 2017-08-17 Bluebird Bio, Inc. Vcn enhancer compositions and methods of using the same
IL261002B2 (en) 2016-02-12 2024-07-01 Bluebird Bio Inc Vcn enhancer compositions and methods of using the same
CA3070172A1 (en) 2017-07-18 2019-01-24 VirTech Bio, Inc. Blood substitutes comprising hemoglobin and methods of making
GB201721503D0 (en) * 2017-12-20 2018-01-31 Univ Essex Modified globin proteins
US10752672B1 (en) * 2019-02-01 2020-08-25 Cheer Global Limited Recombinant hemoglobins and methods of preparation and use thereof
JP7593609B2 (ja) * 2020-02-28 2024-12-03 学校法人 中央大学 ヘモグロビン微粒子及び人工酸素運搬体
US12459820B2 (en) 2020-06-11 2025-11-04 J. W. Randolph Miller Stabilized and NO2-inhibited nitric oxide generating gels for inhaled nitric oxide therapy
WO2022184005A1 (en) 2021-03-01 2022-09-09 Billion King International Limited Thiosuccinyl-crosslinked hemoglobin conjugates and methods of use and preparation thereof
AU2022345865A1 (en) * 2021-09-17 2024-03-14 Yale University Methods, systems and compositions for restoration and preservation of intact organs in a mammal
CN115317595A (zh) * 2021-09-27 2022-11-11 中国人民解放军军事科学院军事医学研究院 一种聚乙二醇化牛血红蛋白氧载体及其制备方法与应用

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3525272A (en) 1967-10-20 1970-08-25 Westinghouse Air Brake Co Multiposition control handle having detent means
DE2449885C3 (de) 1974-10-21 1980-04-30 Biotest-Serum-Institut Gmbh, 6000 Frankfurt Verfahren zur Herstellung von chemisch modifizierten haltbaren Hämoglobinpräparaten sowie das nach diesem Verfahren hergestellte modifizierte Hämoglobinpräparat
US4001401A (en) 1975-02-02 1977-01-04 Alza Corporation Blood substitute and blood plasma expander comprising polyhemoglobin
US4061736A (en) 1975-02-02 1977-12-06 Alza Corporation Pharmaceutically acceptable intramolecularly cross-linked, stromal-free hemoglobin
US4001200A (en) 1975-02-27 1977-01-04 Alza Corporation Novel polymerized, cross-linked, stromal-free hemoglobin
US4053590A (en) 1975-02-27 1977-10-11 Alza Corporation Compositions of matter comprising macromolecular hemoglobin
US4473496A (en) 1981-09-14 1984-09-25 The United States Of America As Represented By The Secretary Of The Army Intramolecularly crosslinked hemoglobin
DE3144705C2 (de) 1981-11-11 1983-12-08 Biotest-Serum-Institut Gmbh, 6000 Frankfurt Verfahren zur Herstellung eines lagerstabilen, vernetzten Hämoglobinpräparates mit hoher Sauerstoff-Transportkapazität, sowie das nach diesem Verfahren hergestellte Hämoglobinpräparat
US4529719A (en) 1983-05-04 1985-07-16 Tye Ross W Modified crosslinked stroma-free tetrameric hemoglobin
US4703008A (en) 1983-12-13 1987-10-27 Kiren-Amgen, Inc. DNA sequences encoding erythropoietin
US4598064A (en) 1984-06-27 1986-07-01 University Of Iowa Research Foundation Alpha-alpha cross-linked hemoglobins
US4600531A (en) 1984-06-27 1986-07-15 University Of Iowa Research Foundation Production of alpha-alpha cross-linked hemoglobins in high yield
US4584130A (en) 1985-03-29 1986-04-22 University Of Maryland Intramolecularly cross-linked hemoglobin and method of preparation
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
US4868119A (en) 1986-12-11 1989-09-19 Genetics Institute, Inc. Hematopoietic growth factors
US4826811A (en) 1986-06-20 1989-05-02 Northfield Laboratories, Inc. Acellular red blood cell substitute
US5032676A (en) 1986-10-14 1991-07-16 Immunex Corporation Nonglycosylated analogs of human colony stimulating factors
DE3636590A1 (de) 1986-10-28 1988-05-26 Braun Melsungen Ag Blutersatzmittel
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
OA09736A (en) 1987-02-18 1993-11-30 Schering Biotech Corp "Human interleukin-3 and muteins thereof".
EP0561245A1 (en) * 1987-05-16 1993-09-22 Somatogenetics International, Inc. Blood substitutes comprising recombinant hemoglobin
GB8711614D0 (en) 1987-05-16 1987-06-24 Medical Res Council Proteins
JP2562840B2 (ja) 1988-08-01 1996-12-11 富士通株式会社 電界効果トランジスタ
IL87707A (en) 1988-09-08 1994-06-24 Technion Inst For Research And Hemoglobin-based blood substitute substantially similar to human blood and method for preparation thereof
US5844090A (en) 1994-05-09 1998-12-01 Somatogen, Inc. Modified hemoglobin-like compounds
US5545727A (en) 1989-05-10 1996-08-13 Somatogen, Inc. DNA encoding fused di-alpha globins and production of pseudotetrameric hemoglobin
US5173426A (en) 1989-10-06 1992-12-22 Yale University DNAs encoding genetically engineered low oxygen affinity mutants of human hemoglobin
JP2657113B2 (ja) 1989-10-16 1997-09-24 アムジエン・インコーポレーテツド 幹細胞因子
US5478806A (en) 1989-11-22 1995-12-26 Enzon, Inc. Enhancement of antitumor therapy with hemoglobin-based conjugates
EP0459788A3 (en) 1990-06-01 1992-01-22 Common Services Agency Modified proteins and methods of producing same
WO1992020369A1 (en) 1991-05-14 1992-11-26 Dana Farber Cancer Institute Use of hemoglobin in a method for the treatment of tumors with chemotherapeutic agents
US5250665A (en) 1991-05-31 1993-10-05 The University Of Toronto Innovations Foundation Specifically β-β cross-linked hemoglobins and method of preparation
US5334706A (en) 1992-01-30 1994-08-02 Baxter International Administration of low dose hemoglobin to increase perfusion
IL106401A (en) 1992-08-07 1997-02-18 Donnelley & Sons Co Method and system for converting bitmap data into page definition language commands
US5840851A (en) 1993-07-23 1998-11-24 Plomer; J. Jeffrey Purification of hemoglobin
TW381022B (en) * 1993-08-16 2000-02-01 Hsia Jen Chang Compositions and methods utilizing nitroxides to avoid oxygen toxicity, particularly in stabilized, polymerized, conjugated, or encapsulated hemoglobin used as a red cell substitute
US5665869A (en) 1993-11-15 1997-09-09 Somatogen, Inc. Method for the rapid removal of protoporphyrin from protoporphyrin IX-containing solutions of hemoglobin
US5559907A (en) 1994-02-17 1996-09-24 Lucent Technologies Inc. Method of controlling polarization properties of a photo-induced device in an optical waveguide and method of investigating structure of an optical waveguide
US6242417B1 (en) 1994-03-08 2001-06-05 Somatogen, Inc. Stabilized compositions containing hemoglobin
US5631219A (en) 1994-03-08 1997-05-20 Somatogen, Inc. Method of stimulating hematopoiesis with hemoglobin
US5585484A (en) 1995-04-19 1996-12-17 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Hemoglobin crosslinkers
US5733869A (en) * 1995-10-06 1998-03-31 Baxter International, Inc. Therapeutic administration of hemoglobin in cardiac arrest
WO1998017289A1 (en) 1996-10-21 1998-04-30 Baxter International Inc. Therapeutic use of hemoglobin to treat head injury
CA2299049C (en) * 1997-05-02 2008-07-15 Baxter Biotech Technology S.A.R.L. Hemoglobin mutants with increased soluble expression and/or reduced nitric oxide scavenging
EP2292657A1 (en) * 1999-11-12 2011-03-09 Baxter Biotech Technology S.A.R.L. Reduced side-effect hemoglobin compositions
EP2340681B1 (en) 2008-09-25 2014-11-12 Nokia Corporation Synchronization for device-to-device communication
US8148264B2 (en) 2009-02-25 2012-04-03 California Institue Of Technology Methods for fabrication of high aspect ratio micropillars and nanopillars
JP5963422B2 (ja) 2010-12-17 2016-08-03 キヤノン株式会社 撮像装置、表示装置、コンピュータプログラムおよび立体像表示システム

Also Published As

Publication number Publication date
NO20022229L (no) 2002-07-11
US6670323B1 (en) 2003-12-30
AU784195B2 (en) 2006-02-16
NO20022229D0 (no) 2002-05-10
US20040259769A1 (en) 2004-12-23
US7211560B2 (en) 2007-05-01
WO2001034648A1 (en) 2001-05-17
AU1759701A (en) 2001-06-06
EP2292657A1 (en) 2011-03-09
ZA200203817B (en) 2003-02-28
EP1233986A4 (en) 2003-01-02
CA2391226A1 (en) 2001-05-17
JP2011098985A (ja) 2011-05-19
JP2003515533A (ja) 2003-05-07
EP1233986A1 (en) 2002-08-28

Similar Documents

Publication Publication Date Title
JP5099951B2 (ja) 副作用が減少されたヘモグロビン組成物
EP1465643B1 (en) Methods and compositions for oxygen transport with high oxygen affinity
US7989414B2 (en) Compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin
US5900402A (en) Method of reducing side effects associated with administration of oxygen-carrying proteins
WO1994027585A1 (en) Methods for improving therapeutic effectiveness of agents for the treatment of solid tumors and other disorders
Conover et al. The ability of polyethylene glycol conjugated bovine hemoglobin (PEG-Hb) to adequately deliver oxygen in both exchange transfusion and top-loaded rat models
JP2012207048A (ja) 酸素運搬成分を使用して血流力学的安定性を増強する方法
US5612310A (en) Methods for improving therapeutic effectiveness of agents for the treatment of solid tumors and other disorders
Vandegriff Haemoglobin-based oxygen carriers
JPH09501441A (ja) 細胞外ヘモグロビンの投与に関連する副作用の処置
US6046170A (en) Therapeutic use of hemoglobin to treat head injury
US20250064771A1 (en) Artificial oxygen carrier blood product
US20250064942A1 (en) Artificial oxygen carrier blood product
US20050119161A1 (en) Methods and compositions for oxygen transport comprising an oxygen carrier and a crystalloid in hypertonic solution
Barnikol et al. Haemoglobin Hyperpolymers, a New Type of Artificial Oxygen Carrier–Concept and Current State of Development
EP4041193A1 (en) Stabilized hemoglobin compositions and pharmaceutical formulations thereof
Beauchesne The Design of Blood Substitutes: Oxygen Carriers
EP1894573A2 (en) Methods and compositions for oxygen transport comprising a high oxygen affinity

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071106

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20071106

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101015

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110114

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110121

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110215

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110614

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110913

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110921

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111004

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120227

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120620

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20120705

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120904

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120925

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20151005

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees